MOST Plus (My Own Specific Treatment) - A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510566-27-00

Acronym

ET-12-081

Enrollment

900

Registered

2024-10-01

Start date

2014-02-27

Completion date

Unknown

Last updated

2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced / Metastatic cancers

Brief summary

Induction period: The 12-week Progression-Free Rate (PFR) or 52-week PFR for IT, Maintenance period Progression-Free Survival (PFS)

Detailed description

- Induction period The Objective Response Rate (ORR), - Maintenance period Secondary endpoints of the maintenance period will be analyzed on the ITT population. Overall survival (OS) and EORTC QLQ-C30 scores, - Whole study period Progression-Free Survival, - Whole study period: The duration of response, - Whole study period: Safety assessment

Interventions

DRUGLynparza 100 mg film-coated tablets

DRUGIMJUDO 20 mg/ml concentrate for solution for infusion.

DRUGTasigna 200 mg hard capsules

DRUGLynparza 150 mg film-coated tablets

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Induction period: The 12-week Progression-Free Rate (PFR) or 52-week PFR for IT, Maintenance period Progression-Free Survival (PFS)	—

Secondary

Measure	Time frame
- Induction period The Objective Response Rate (ORR), - Maintenance period Secondary endpoints of the maintenance period will be analyzed on the ITT population. Overall survival (OS) and EORTC QLQ-C30 scores, - Whole study period Progression-Free Survival, - Whole study period: The duration of response, - Whole study period: Safety assessment	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026